{"id":"nadolol-ismn","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Nitrate tolerance"}]},"_chembl":{"chemblId":"CHEMBL521606","moleculeType":"Small molecule","molecularWeight":"309.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nadolol is a non-selective beta-adrenergic antagonist that decreases heart rate, contractility, and blood pressure, reducing myocardial oxygen demand. ISMN is a nitrate vasodilator that relaxes vascular smooth muscle, improving coronary perfusion and reducing preload on the heart. Together, this combination provides complementary cardioprotective effects for angina management.","oneSentence":"Nadolol reduces heart rate and blood pressure via beta-blockade, while ISMN (isosorbide mononitrate) dilates blood vessels to improve coronary blood flow and reduce cardiac workload.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:56:30.805Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Angina pectoris"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT01103154","phase":"PHASE4","title":"A Trial of Nadolol Plus Isosorbide Mononitrate Versus Carvedilol for the Prevention of Variceal Rebleeding","status":"COMPLETED","sponsor":"E-DA Hospital","startDate":"2005-03","conditions":"Variceal Rebleeding","enrollment":121},{"nctId":"NCT00563602","phase":"PHASE4","title":"Treatment for Prevention of Variceal Rebleeding Guided by the Hemodynamic Response","status":"UNKNOWN","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2007-08","conditions":"Portal Hypertension, Complications of Cirrhosis","enrollment":140},{"nctId":"NCT00450164","phase":"PHASE4","title":"Secondary Prophylaxis After Variceal Bleeding in Non-Responders","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2000-11","conditions":"Gastrointestinal Hemorrhage, Portal Hypertension, Cirrhosis","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"nadolol + ISMN","genericName":"nadolol + ISMN","companyName":"E-DA Hospital","companyId":"e-da-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nadolol reduces heart rate and blood pressure via beta-blockade, while ISMN (isosorbide mononitrate) dilates blood vessels to improve coronary blood flow and reduce cardiac workload. Used for Angina pectoris, Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}